ProfileGDS5678 / 1416670_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 7% 7% 7% 8% 7% 7% 7% 7% 7% 7% 7% 7% 7% 8% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.191087
GSM967853U87-EV human glioblastoma xenograft - Control 22.167187
GSM967854U87-EV human glioblastoma xenograft - Control 32.1727
GSM967855U87-EV human glioblastoma xenograft - Control 42.136628
GSM967856U87-EV human glioblastoma xenograft - Control 52.114077
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.212457
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.181767
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.151117
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.144347
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.157157
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.154357
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.141867
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.162427
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.18338